Professor of Medicine
Dept of Clinical and Experimental Medicine
University of Leuven, Belgium
Chief, Division of Hepato-Gastroenterology
University Hospitals, Leuven
Clinical Adjunct, Dept of Medicine
University of Toronto, Ontario, Canada
I am delighted to welcome you to one of two Takeda-organized educational symposia at UEG Week 2015: “Gut-Selective Biologic Therapy for Ulcerative Colitis: Lessons From Science and Practice.”
Although ulcerative colitis (UC) and Crohn’s disease (CD) are both inflammatory bowel diseases, they are two distinct disorders with different clinical, endoscopic, and pathologic findings. Because of their differences regarding therapeutic approaches, responses, and goals, clinical separation of these two disease entities is important. This symposium will focus on the use of biologics, including new gut-selective therapy, for the treatment of UC. Discussion of biologics for the treatment of CD will take place at a second educational symposium on Wednesday, 28 October (07:00-08:00, Room B2, Fira de Barcelona).
The optimal therapeutic goals in the management of UC include the induction and maintenance of clinical remission. Axel Dignass will review current biologics, including the anti-tumor necrosis factor (TNF) drugs adalimumab, golimumab, and infliximab, and the gut-selective anti-integrin antibody vedolizumab, all of which have demonstrated efficacy in achieving these treatment goals. Based on the success of these biologics, Prof Dr Dignass will explore the feasibility of adding mucosal healing and patient-reported remission to the therapeutic goals for UC.
The availability of 4 effective biologics brings new challenges to the management of patients with moderate-severe UC such as how to choose a first-line biologic. Based on her clinical experience, Britta Siegmund will offer guidance on how to determine the best treatment, taking into consideration patient comorbidities and preference and, most importantly, the benefit-risk evidence for each biologic.
In clinical trials, vedolizumab has been shown to effectively induce and maintain remission without systemic immunosuppressive effects. This prompts the question of how these clinical trial data translate to everyday clinical practice. William Sandborn will present an analysis of the clinical outcomes and safety associated with vedolizumab in patients with moderate–severe UC in a real-world setting.
We believe you will find this symposium provides clinical insights that you can incorporate into your own approach to managing patients with UC. I, along with my three fellow faculty members, thank you for joining us this evening and hope you enjoy this event.
Gert Van Assche, MD, PhD, AGAF, FACG